الفهرس 
صفحة العنوان باللغة الانجليزيةOnly 14 pages are availabe for public view
 |  | from | 207 |  |  |
| | | from | 207 | | |
Abstract
H
epatitis C is a disease with a significant global impact. About 130-150 million people are chronically infected with the hepatitis C virus (HCV), representing about 2-2.5% of the world’s population. In Egypt, the prevalence is 10% and according to the last DHS in 2015, it was 7%.
New DAA drugs have been introduced over the past few years, and an example of these drugs is the combination of sofosbuvir and daclatasvir, which is widely used in Egypt nowadays.
Being a hepatotropic and lymphotropic virus, HCV does not cause hepatic manifestations only; it also leads to a significant number of extra-hepatic manifestations. Around 74% of patients with HCV will show HCV-related extrahepatic manifestations in their lifetime.
The association of chronic HCV infection with a wide spectrum of cutaneous manifestations has been widely reported in the literature, with varying strength of epidemiological association. About 17% of HCV patients present at least one skin manifestation, which can be directly or indirectly induced by chronic HCV infection.
The current study included thirty HCV positive Egyptian patients who experienced extrahepatic cutaneous manifestations (6 patients with classic lichen planus, 8 patients with psoriasis vulgaris and 16 patients with hepatic pruritus), from those who received treatment at New Cairo viral hepatitis center, one of the NCCVH centers, from October 2018 to July 2019